SEC Tracker
Get the app

Alaunos Therapeutics TCRT

Alaunos Therapeutics acquires Velaris

Form
8-K
Filed
Importance
Routine
  1. Acquired Velaris Therapeutics on Oct 13, 2026
  2. Issued 105,286 Series B Preferred Stock and 33,054 Series C Preferred Stock
  3. Agreed to increase Common Stock authorization and change company name
  4. Received $350 million in private placement financing

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Alaunos Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. BioCardia BCDA public float $10M, Jun 30, 2025
  2. Raphael Pharmaceutical RAPH public float $9M, Jun 30, 2025
  3. Traws Pharma ONTX public float $10M, Jun 30, 2025
  4. Mannatech MTEX public float $10M, Jun 30, 2025
  5. Bioxytran BIXT public float $9M, Jun 30, 2025